This HTML5 document contains 75 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00680/identifier/pharmgkb/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00680/identifier/kegg-compound/
n15http://linked.opendata.cz/resource/drugbank/company/
n25http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n19http://linked.opendata.cz/resource/drugbank/drug/DB00680/identifier/pubchem-compound/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00680/identifier/pubchem-substance/
n18http://linked.opendata.cz/resource/drugbank/drug/DB00680/identifier/kegg-drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00680/identifier/drugbank/
n6http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n16http://linked.opendata.cz/resource/drugbank/drug/DB00680/identifier/national-drug-code-directory/
n22http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n12http://linked.opendata.cz/resource/drugbank/drug/DB00680/identifier/chemspider/
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n8http://www.drugs.com/cdi/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00680/identifier/chebi/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n10http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00680/identifier/wikipedia/
n9http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00680
rdf:type
n3:Drug
n3:description
An antiarrhythmia agent used primarily for ventricular rhythm disturbances. [PubChem]
n3:group
approved withdrawn
n3:halfLife
2 hours (range 1.5-3.5 hours).
n3:indication
Used to treat irregular heartbeats (arrhythmias) and maintain a normal heart rate.
n3:manufacturer
n15:271B4304-363D-11E5-9242-09173F13E4C5
owl:sameAs
n6:DB00680 n22:DB00680
dcterms:title
Moricizine
adms:identifier
n12:31872 n13:DB00680 n14:6997 n16:54092-046-01 n17:C07743 n18:D05077 n19:34633 n20:46509072 n21:PA164747738 n23:Moricizine
n3:mechanismOfAction
Moricizine works by inhibiting the rapid inward sodium current across myocardial cell membranes.
n3:packager
n15:271B4303-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Less than 1% of orally administered Ethmozine® is excreted unchanged in the urine. Approximately 56% of the administered dose is excreted in the feces and 39% is excreted in the urine.
n3:synonym
Ethyl 10-(beta-N-morpholinylpropionyl)phenothiazine-2-carbamate Moracizin Ethmozin Moracizine EN-313 Etmozin Ethyl 10-(3-morpholinopropionyl)phenothiazine-2-carbamate Moricizine [10-(3-Morpholin-4-yl-propionyl)-10H-phenothiazin-2-yl]-carbamic acid ethyl ester Moracizinum Moracizina
n3:toxicity
Symptoms of overdose include vomiting, unconsciousness, and severe low blood pressure.
n3:volumeOfDistribution
* 300 L
n3:proteinBinding
Approximately 95%.
n3:salt
n3:synthesisReference
"DrugSyn.org":http://www.drugsyn.org/Moricizine.htm
n24:hasConcept
n25:M0024900
foaf:page
n8:moricizine.html
n3:IUPAC-Name
n4:271B4309-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B430F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B430E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B430B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B430C-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B430D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B431F-363D-11E5-9242-09173F13E4C5 n4:271B4307-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4321-363D-11E5-9242-09173F13E4C5 n4:271B4305-363D-11E5-9242-09173F13E4C5 n4:271B4308-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4306-363D-11E5-9242-09173F13E4C5
n9:hasATCCode
n10:C01BG01
n3:H-Bond-Acceptor-Count
n4:271B4315-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4316-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B4310-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B4311-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B4313-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B4312-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B4314-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed, absorption is complete within 2 to 3 hours. Significant first-pass metabolism results in an absolute bioavailability of approximately 38%. Administration within 30 minutes after a meal slows the rate, but does not affect the extent of absorption, although peak plasma concentrations are reduced.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
31883-05-3
n3:category
n3:Bioavailability
n4:271B431B-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B431D-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B431E-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B4320-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B431A-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4319-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B431C-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B430A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4317-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4318-363D-11E5-9242-09173F13E4C5